Stephen H.

Stephen H. is a seasoned medical affairs professional with extensive experience as a Medical Science Liaison (MSL) and Medical Director across several prominent companies in the pharmaceutical industry. Notable roles include serving as a Clinical Science Liaison at Aerocrine, a Medical Science Liaison at Mylan where a generic Glatiramer Acetate for Multiple Sclerosis was launched, and leading initiatives for advanced prostate cancer therapies at Novartis, including the launch of Pluvicto™ and Locametz®. Stephen H. has contributed to clinical trial design and execution, demonstrating significant success in patient enrollment and diversity participation, and currently holds the position of Medical Director at AstraZeneca, focusing on tumor-agnostic therapies. Academic credentials include a Doctor of Medicine from American University of the Caribbean, a Bachelor of Science in Biology from the University of Virginia, and an MBA from American Public University.